Designer GLP1 poly-agonist peptides in the management of diabesity

Laura Statham; Melina Pelling; Petra Hanson; Ioannis Kyrou; Harpal Randeva; Thomas M Barber

doi:10.1080/17446651.2023.2204976

Designer GLP1 poly-agonist peptides in the management of diabesity

Laura Statham, Melina Pelling, Petra Hanson, Ioannis Kyrou, Harpal Randeva, Thomas M Barber

Centre for Health and Life Sciences

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

77 Downloads (Pure)

Abstract

Introduction: To date, the 21 ^st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the ‘designer’ GLP1 Poly-agonist Peptides (GLP1PPs). Areas covered: A PubMed search of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development. Expert opinion: At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.

Original language	English
Pages (from-to)	231-240
Number of pages	10
Journal	Expert review of endocrinology & metabolism
Volume	18
Issue number	3
DOIs	https://doi.org/10.1080/17446651.2023.2204976
Publication status	Published - 24 Apr 2023

Bibliographical note

© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent

Keywords

Diabesity
Glucagon Like Peptide 1
Incretin
diabetes
obesity

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/17446651.2023.2204976Licence: CC BY-NC-ND

PublishedFinal published version, 781 KBLicence: CC BY-NC-ND
Designer GLP1 poly agonist peptides in the management of diabesityFinal published version, 779 KB

Cite this

@article{9e8a1205f2954be4b9f9f185c24a993f,

title = "Designer GLP1 poly-agonist peptides in the management of diabesity",

abstract = "Introduction: To date, the 21 st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the {\textquoteleft}designer{\textquoteright} GLP1 Poly-agonist Peptides (GLP1PPs). Areas covered: A PubMed search of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development. Expert opinion: At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.",

keywords = "Diabesity, Glucagon Like Peptide 1, Incretin, diabetes, obesity",

author = "Laura Statham and Melina Pelling and Petra Hanson and Ioannis Kyrou and Harpal Randeva and Barber, {Thomas M}",

note = "{\textcopyright} 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent",

year = "2023",

month = apr,

day = "24",

doi = "10.1080/17446651.2023.2204976",

language = "English",

volume = "18",

pages = "231--240",

journal = "Expert review of endocrinology & metabolism",

issn = "1744-8417",

publisher = "Taylor and Francis Group",

number = "3",

}

TY - JOUR

T1 - Designer GLP1 poly-agonist peptides in the management of diabesity

AU - Statham, Laura

AU - Pelling, Melina

AU - Hanson, Petra

AU - Kyrou, Ioannis

AU - Randeva, Harpal

AU - Barber, Thomas M

N1 - © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent

PY - 2023/4/24

Y1 - 2023/4/24

N2 - Introduction: To date, the 21 st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the ‘designer’ GLP1 Poly-agonist Peptides (GLP1PPs). Areas covered: A PubMed search of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development. Expert opinion: At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.

AB - Introduction: To date, the 21 st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the ‘designer’ GLP1 Poly-agonist Peptides (GLP1PPs). Areas covered: A PubMed search of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development. Expert opinion: At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.

KW - Diabesity

KW - Glucagon Like Peptide 1

KW - Incretin

KW - diabetes

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=85153584829&partnerID=8YFLogxK

U2 - 10.1080/17446651.2023.2204976

DO - 10.1080/17446651.2023.2204976

M3 - Review article

C2 - 37089108

SN - 1744-8417

VL - 18

SP - 231

EP - 240

JO - Expert review of endocrinology & metabolism

JF - Expert review of endocrinology & metabolism

IS - 3

ER -

Designer GLP1 poly-agonist peptides in the management of diabesity

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this